XBI241129C90500
- 6.00
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
How Is The Market Feeling About United Therapeutics?
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 InMIND Results And Virtual Analyst Event On December 12
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Top 3 Health Care Stocks That May Dip This Month
Price Over Earnings Overview: Gilead Sciences
Analyst Expectations For Sarepta Therapeutics's Future
Sarepta Therapeutics Analyst Ratings
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC